• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Lumiracoxib

Lumiracoxib

Product ID L8248
Cas No. 220991-20-8
Purity ≥98%
Product Unit SizeCostQuantityStock
25 mg $67.80 In stock
100 mg $183.10 In stock
250 mg $352.30 In stock
1 g $1,070.70 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Lumiracoxib is a non-steroidal anti-inflammatory drug (NSAID) that acts as an inhibitor of COX enzymes with specificity for COX-2. Like other NSAIDs, lumiracoxib exhibits anti-inflammatory, analgesic, antipyretic, and antinociceptive activities. In animal models of metabolic syndrome, lumiracoxib reverses vascular remodeling and inflammation. In animal models with experimental autoimmune encephalitis (EAE, a translational model of multiple sclerosis), lumiracoxib inhibits lymphocyte responses and decreases disease severity; in similar in vitro models, lumiracoxib inhibits T cell proliferation and modulates expression of T-bet, IL-10, and IFN-γ. This compound may also inhibit thromboxane receptors. Additionally, lumiracoxib exhibits some anticancer potential, inducing G0/G1 cell cycle arrest and apoptosis and inhibiting proliferation in non-small cell lung cancer (NSCLC) cell lines.

Product Info

Cas No.

220991-20-8

Purity

≥98%

Formula

C15H13ClFNO2

Formula Wt.

293.72

Chemical Name

2-[(2-Chloro-6-fluorophenyl)amino]-5-methylbenzeneacetic acid

IUPAC Name

2-[2-(2-chloro-6-fluoroanilino)-5-methylphenyl]acetic acid

Melting Point

158-159°C

Appearance

Pale Yellow Crystal

Shipping and Storage

Store Temp

Ambient

Ship Temp

Ambient

Downloads

MSDS

L8248 MSDS PDF

Info Sheet

L8248 Info Sheet PDF

References

Windsor MA, Valk PL, Xu S, et al. Exploring the molecular determinants of substrate-selective inhibition of cyclooxygenase-2 by lumiracoxib. Bioorg Med Chem Lett. 2013 Nov 1;23(21):5860-4. PMID: 24060487.

Renna NF, Diez ER, Lembo C, et al. Role of Cox-2 in vascular inflammation: an experimental model of metabolic syndrome. Mediators Inflamm. 2013;2013:513251. PMID: 23476105.

Hao JQ, Li Q, Xu SP, et al. Effect of lumiracoxib on proliferation and apoptosis of human nonsmall cell lung cancer cells in vitro. Chin Med J (Engl). 2008 Apr 5;121(7):602-7. PMID: 18466679.

Selg E, Buccellati C, Andersson M, et al. Antagonism of thromboxane receptors by diclofenac and lumiracoxib. Br J Pharmacol. 2007 Dec;152(8):1185-95. Erratum in: Br J Pharmacol. 2008 Apr;153(8):1763. Ambrosio, E [corrected to Ambrosio, M]. PMID: 17965743.

Ni J, Shu YY, Zhu YN, et al. COX-2 inhibitors ameliorate experimental autoimmune encephalomyelitis through modulating IFN-gamma and IL-10 production by inhibiting T-bet expression. J Neuroimmunol. 2007 May;186(1-2):94-103. PMID: 17442406.

Esser R, Berry C, Du Z, et al. Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. Br J Pharmacol. 2005 Feb;144(4):538-50. PMID: 15655513.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • G7541

    GSK-1904529A

    InsR and IGF-1R inhibitor.

    ≥98%
  • R1626

    Regorafenib Monohydrate

    VEGFR1/2/3, TIE2, PDGFRβ, FGFR1, c-Kit, RET, B...

    ≥99%
  • M3377

    Mitomycin C

    Alkaloid produced by Streptomyces, DNA cross-li...

    ≥98%
  • O1178

    n-Octyl-3-methylcaffeate

    Derivative of methyl caffeate, hydroxycinnamic ...

    ≥98%
  • T1673

    Terlipressin Acetate

    Synthetic peptide, vasopressin analog; AVPR1 ag...

    ≥95%
  • P2919

    L-Phenylalaninol

    Non-essential amino acid alcohol.

    ≥98%
  • R1879

    Retinyl Palmitate

    Vitamin A derivative, palmitic acid ester of re...

    ≥1.70 MIU/g, bio assay
  • S9775

    Systemin

    Peptide hormone found in Solanaceae family plan...

    ≥95%
  • N3228

    Nifedipine

    Dihydropyridine; L-type Ca2+ channel blocker.

    ≥98%
  • B6816

    Brefeldin A

    Lactone found in fungi such as Eupenicillium; g...

    ≥97%
  • C291342

    CHIR-99021

    GSK3 inhibitor.

    ≥98%
  • T3200

    Ticagrelor

    Nucleoside (adenosine) analog; P2Y12 antagonist...

    ≥98%
  • A4926

    AMG-458

    c-MET inhibitor.

    ≥98%
  • T3324

    Tigecycline

    Glycylcycline; protein synthesis inhibitor.

    ≥98%
  • N6272

    NPS-2143 Hydrochloride

    Ca2+-sensing receptor antagonist.

    ≥99%
  • T5846

    Tolfenamic Acid

    NSAID; COX-1/2 inhibitor.

    ≥98%
  • V0148

    Valproic Acid

    T-type Ca2+ and voltage-gated Na+ channel block...

    ≥98%
  • P2512

    S-(N-Phenethylthiocarbamoyl)-L-cysteine

    Cysteine-ITC conjugate, antioxidant.

    ≥98%
  • N5409

    Nocodazole

    Microtubule polymerization inhibitor.

    ≥98%
  • M4200

    MK-0752

    γ-Secretase inhibitor.

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only